South Korea Heparin Market

ID: MRFR/HC/50581-HCR
200 Pages
Satyendra Maurya
Last Updated: February 06, 2026
South Korea Heparin Market Research Report: Size, Share, Trend Analysis By Product (Unfractionated Heparin (UFH), Low Molecular Weight Heparin (LMWH), By Source (Bovine, Porcine), By Applications (Deep Vein Thrombosis & Pulmonary Embolism, Atrial Fibrillation, Heart Attacks, Stroke, Others), By Route of Administration (Intravenous Infusion, Subcutaneous Injection) and By End Users (Hospitals & ASCS, Clinics, Others) - Growth Outlook & Industry Forecast 2025 To 2035
South Korea Heparin Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)3.46%
2024 Market Size$ 296.7 Million
2025 Market Size$ 306.97 Million
2035 Market Size$ 431.1 Million
Key Players
Boehringer Ingelheim
Sanofi
Pfizer
Novartis
Mylan
Teva Pharmaceutical Industries
Trends
  • Rising Demand for Anticoagulants
  • Focus on Innovative Formulations
  • Sustainability in Production
Opportunities
  • Advancements in Medical Technology
  • Increasing Cardiovascular Diseases
  • Expansion of Healthcare Infrastructure
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Security, Access Control and Robotics, BY Product (USD Million)
      1. 4.1.1 Unfractionated Heparin (UFH)
      2. 4.1.2 Low Molecular Weight Heparin (LMWH)
    2. 4.2 Security, Access Control and Robotics, BY Source (USD Million)
      1. 4.2.1 Bovine
      2. 4.2.2 Porcine
    3. 4.3 Security, Access Control and Robotics, BY Application (USD Million)
      1. 4.3.1 Deep Vein Thrombosis & Pulmonary Embolism
      2. 4.3.2 Atrial Fibrillation
      3. 4.3.3 Heart Attacks
      4. 4.3.4 Stroke
      5. 4.3.5 Others
    4. 4.4 Security, Access Control and Robotics, BY Route of Administration (USD Million)
      1. 4.4.1 Intravenous Infusion
      2. 4.4.2 Subcutaneous Injection
    5. 4.5 Security, Access Control and Robotics, BY End user (USD Million)
      1. 4.5.1 Hospitals & ASCS
      2. 4.5.2 Clinics
      3. 4.5.3 Others
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Security, Access Control and Robotics
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Security, Access Control and Robotics
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Boehringer Ingelheim (DE)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Sanofi (FR)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Pfizer (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Novartis (CH)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Mylan (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Teva Pharmaceutical Industries (IL)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Aspen Pharmacare (ZA)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Hepalink (CN)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Luitpold Pharmaceuticals (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 SOUTH KOREA MARKET ANALYSIS BY PRODUCT
    3. 6.3 SOUTH KOREA MARKET ANALYSIS BY SOURCE
    4. 6.4 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
    5. 6.5 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    6. 6.6 SOUTH KOREA MARKET ANALYSIS BY END USER
    7. 6.7 KEY BUYING CRITERIA OF SECURITY, ACCESS CONTROL AND ROBOTICS
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF SECURITY, ACCESS CONTROL AND ROBOTICS
    10. 6.10 DRIVERS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
    12. 6.12 SUPPLY / VALUE CHAIN: SECURITY, ACCESS CONTROL AND ROBOTICS
    13. 6.13 SECURITY, ACCESS CONTROL AND ROBOTICS, BY PRODUCT, 2024 (% SHARE)
    14. 6.14 SECURITY, ACCESS CONTROL AND ROBOTICS, BY PRODUCT, 2024 TO 2035 (USD Million)
    15. 6.15 SECURITY, ACCESS CONTROL AND ROBOTICS, BY SOURCE, 2024 (% SHARE)
    16. 6.16 SECURITY, ACCESS CONTROL AND ROBOTICS, BY SOURCE, 2024 TO 2035 (USD Million)
    17. 6.17 SECURITY, ACCESS CONTROL AND ROBOTICS, BY APPLICATION, 2024 (% SHARE)
    18. 6.18 SECURITY, ACCESS CONTROL AND ROBOTICS, BY APPLICATION, 2024 TO 2035 (USD Million)
    19. 6.19 SECURITY, ACCESS CONTROL AND ROBOTICS, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    20. 6.20 SECURITY, ACCESS CONTROL AND ROBOTICS, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
    21. 6.21 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END USER, 2024 (% SHARE)
    22. 6.22 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END USER, 2024 TO 2035 (USD Million)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY PRODUCT, 2025-2035 (USD Million)
      2. 7.2.2 BY SOURCE, 2025-2035 (USD Million)
      3. 7.2.3 BY APPLICATION, 2025-2035 (USD Million)
      4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
      5. 7.2.5 BY END USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

South Korea South Korea Heparin Market Segmentation

South Korea Heparin Market By Product (USD Million, 2025-2035)

  • Unfractionated Heparin (UFH)
  • Low Molecular Weight Heparin (LMWH)

South Korea Heparin Market By Source (USD Million, 2025-2035)

  • Bovine
  • Porcine

South Korea Heparin Market By Application (USD Million, 2025-2035)

  • Deep Vein Thrombosis & Pulmonary Embolism
  • Atrial Fibrillation
  • Heart Attacks
  • Stroke
  • Others

South Korea Heparin Market By Route of Administration (USD Million, 2025-2035)

  • Intravenous Infusion
  • Subcutaneous Injection

South Korea Heparin Market By End user (USD Million, 2025-2035)

  • Hospitals & ASCS
  • Clinics
  • Others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.